|
|
|
Volumn 1, Issue 2, 2001, Pages 166-
|
|
MedImmune initiates phase I/II clinical study with Vitaxin.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY LM 609;
ARTICLE;
COLORECTAL TUMOR;
DRUG INDUSTRY;
HUMAN;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
COLORECTAL NEOPLASMS;
DRUG INDUSTRY;
HUMANS;
|
|
EID: 0035427914
PISSN: 14737140
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (4)
|
|
References (0)
|